Natalie Holles, Third Harmonic Bio CEO
December 15, 2022 09:39 AM ESTUpdated 10:33 AM
R&D

Dis­con­tin­u­a­tion day: Third Har­mon­ic’s on­ly drug fails safe­ty study as BioCryst culls pipeline af­ter ASH

Kyle LaHucik

Senior Reporter

Third Har­mon­ic Bio is call­ing it quits on its lead tri­al just three months af­ter be­ing one of the few biotech IPOs this year, and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

A service from the Financial Times